Miltefosine - discovery of the antileishmanial activity of phospholipid derivatives
Miltefosine - discovery of the antileishmanial activity of phospholipid derivatives
复制标题
DOI：
10.1016/j.trstmh.2006.03.009
复制
发表时间：
2006-12-01
影响因子：
2.2
通讯作者：
Engel, Juergen
中科院分区：
文献类型：
--
作者：
Croft, Simon L.;Engel, Juergen
Miltefosine（十六烷基磷酸胆碱，Impavido（TM））是一种用于治疗内脏和皮肤利什曼病的新型抗原生动物药物，在20世纪80年代早期在德国被鉴定为潜在的抗癌药物，在英国被鉴定为抗利什曼病药物。虽然米替福新不是该类化合物中体外抗利什曼原虫活性最强的化合物，但在内脏利什曼病实验模型中口服给药后的早期活性证明有助于引起WHO TDR的注意，以便在与制药行业（Zentaris GmbH）的独特合作模式中进一步开发该化合物。米替福新对大多数利什曼原虫有活性，包括那些引起皮肤疾病的利什曼原虫。(c)2006年皇家热带医学和卫生学会。由爱思唯尔有限公司出版。保留所有权利。
Miltefosine (hexadecylphosphocholine, Impavido (TM)), a novel antiprotozoal drug used for the treatment of visceral and cutaneous leishmaniasis, was identified and evaluated independently in the early 1980s as a potential anticancer drug in Germany and as an antileishmanial drug in the UK. Although miltefosine is not the most active compound of its class against Leishmania parasites in vitro, the early demonstration of activity after oral administration in experimental models of visceral leishmaniasis helped to bring this compound to the attention of WHO TDR for further development in a unique collaboration model-with the pharmaceutical industry (Zentaris GmbH). Miltefosine is active against most Leishmania species, including those that cause cutaneous disease. (c) 2006 Royal Society of Tropical Medicine and Hygiene. Published by Elsevier Ltd. All rights reserved.